ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia

Blood

Volumn 94, Issue 7, 1999, Pages 2452-2460

  Asimakopoulos, Fotis A ^a   Shteper, Pesach J ^a   Krichevsky, Svetlana ^a   Fibach, Eitan ^a   Polliack, Aaron ^a   Rachmilewitz, Eliezer ^a   Ben Neriah, Yinon ^a   Ben Yehuda, Dina ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ALLELE; ARTICLE; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLONE; DNA SEQUENCE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; METHYLATION; ONCOGENE; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION;

EID: 0033214222     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.7.2452.419k23_2452_2460     Document Type: Article

References (42)

1. Fialkow PJ, Martin PJ, Najfeld V, Penfold GK, Jacobson RJ, Hansen JA: Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood 58:158, 1981
2. Martin PJ, Najfeld V, Hansen JA, Penfold GK, Jacobson RJ, Fialkow PJ: Involvement of the B-lymphoid system in chronic myelogenous leukaemia. Nature 287:49, 1980
3. Golde DW, Brugaleta C, Sparkes RS, Cline MJ: The Philadelphia chromosome in human macrophages. Blood 49:367, 1977
4. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 132:1497, 1960
5. Sawyers CL: The bcr-abl gene in chronic myelogenous leukaemia. Cancer Surv 15:37, 1992
6. Kantarjian HM, Deisseroth AB, Kurzrock R, Estrov Z, Talpaz M: Chronic myelogenous leukemia: A concise update. Blood 82:691, 1993
7. Melo JV: The molecular biology of chronic myeloid leukemia. Leukemia 10:751, 1996
8. Wang JYJ: Abl tyrosine kinase in signal transduction and cell cycle regulation. Curr Opin Genet Dev 3:35, 1993
9. Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, Yen T, Hobson K, Gatei M, Zhang N, Watters D, Egerton M, Shiloh Y, Kharbanda S, Kufe D, Lavin MF: Interaction between ATM protein and c-Abl in response to DNA damage. Nature 387:520, 1997
10. Ahuja H, Bar-Eli M, Arlin Z, Advani S, Allen SL, Goldman JM, Snyder D, Foti A, Cline M: The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 87:2042, 1991
11. Majlis A, Smith TL, Talpaz M, O'Brien S, Rios MB, Kantarjian HM: Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 14:196, 1996
12. Miyamura K, Barrett AJ, Kodera Y, Saito H: Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: A review of recent results. Bone Marrow Transplant 14:201, 1994
13. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E: Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 47:277, 1986
14. Ben-Neriah Y, Bernards A, Paskind M, Daley GQ, Baltimore D: Alternative 5′ exons in c-abl mRNA. Cell 44:577, 1986
15. Jiang XY, Trujillo JM, Dao D, Liang JC: Studies of BCR and ABL gene rearrangements in chronic myelogenous leukemia patients by conventional and pulsed-field gel electrophoresis using gel inserts. Cancer Genet Cytogenet 42:287, 1989
16. Zion M, Ben-Yehuda D, Avraham A, Cohen O, Wetzler M, Melloul D, Ben-Neriah Y: Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci USA 91:10722, 1994
17. Ben-Yehuda D, Krichevsky S, Rachmilewitz EA, Avraham A, Palumbo GA, Frassoni F, Sahar D, Rosenbaum H, Paltiel O, Zion M, Ben-Neriah Y: Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia. Blood 90:4918, 1997
18. Issa J.-P.J, Kantarjian H, Mohan A, O'Brien S, Cortes J, Pierce S, Talpaz M: Methylation of the ABL1 promoter in chronic myelogenous leukemia: Lack of prognostic significance. Blood 93:2075, 1999
19. Willer A, Kramer A, Saussele S, Hochhaus A, Seifath W, Hehlmann R: Disease progression in chronic myelogenous leukemia (CML) is linked to methylation of the ABL promoter. Blood 90:196a, 1997(abstr, suppl 1)
20. Randhawa GS, Cui H, Barletta JA, Strichman-Almashanu LZ, Talpaz M, Kantarjian H, Deisseroth AB, Champlin R, Feinberg A: Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood 91:3144, 1998
21. Malinen T, Palotie A, Pakkala S, Peltonen L, Ruutu T, Jansson SE: Acceleration of chronic myeloid leukemia correlates with calcitonin gene hypermethylation. Blood 77:2435, 1991
22. Litz CE, McClure JS, Coad JE, Goldfarb AN, Brunning RD: Methylation status of the major breakpoint cluster region in Philadelphia chromosome negative leukemias. Leukemia 6:35, 1992
23. Mills KI, Sproul AM, Ogilvie D, Elvin P, Leibowitz D, Burnett AK: Amplification and sequencing of genomic breakpoints located within the M-bcr region by Vectorette-mediated polymerase chain reaction. Leukemia 6:481, 1992
24. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821, 1996
25. Guo XYD, Fontana J, Kufe D, Deisseroth A: Antagonistic effects of ABL and BCRABL proteins on proliferation and the response to genotoxic stress in normal and leukemia myeloid cells. Leuk Lymphoma 30:225, 1998
26. Peled T, Rigel M, Peritt D, Fibach E, Treves AJ, Barak V: Effect of M-20 interleukin-1 inhibitor on normal and leukemic human myeloid progenitors. Blood 79:1172, 1992
27. Kolodner R: Biochemistry and genetics of eukaryotic mismatch repair. Genes Dev 10:1433, 1996
28. Perucho M: Cancer of the microsatellite mutator phenotype. Biol Chem 377:675, 1996
29. Papadopoulos N, Lindblom A: Molecular basis of HNPCC: Mutations of MMR genes. Hum Mutat 10:89, 1997
30. Prolla TA: DNA mismatch repair and cancer. Curr Opin Cell Biol 10:311, 1998
31. de la Chapelle A, Peltomaki P: The genetics of hereditary common cancers. Curr Opin Genet Dev 8:298, 1998
32. Wiesendanger M, Scharff MD, Edelmann W: Somatic hypermutation, transcription, and DNA mismatch repair. Cell 94:415, 1998
33. Gartenhaus RB: Microsatellite instability in hematologic malignancies. Leuk Lymphoma 25:455, 1997
34. Rotman G, Shiloh Y: ATM: From gene to function. Hum Mol Genet 7:1555, 1998
35. Morgan SE, Kastan MB: p53 and ATM: Cell cycle, cell death, and cancer. Adv Cancer Res 71:1, 1997
36. Wada C, Shionoya S, Fujino Y, Tokuhiro H, Akahoshi T, Uchida T, Ohtani H: Genomic instability of microsatellite repeats and its association with the evolution of chronic myelogenous leukemia. Blood 83:3449, 1994
37. Silly H, Chase A, Mills K, Apfelbeck U, Sormann S, Goldman JM, Cross NCP: No evidence of microsatellite instability or consistent loss of heterozygosity at selected loci in chronic myeloid leukemia blast crisis. Leukemia 8:1923, 1994
38. Edelmann W, Yang K, Umar A, Heyer J, Lau K, Fan K, Liedtke W, Cohen P, Kane MF, Lipford JR, Yu N, Crouse GF, Pollard JW, Kunkel T, Lipkin M, Kolodner R, Kucherlapati R: Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 91:467, 1997
39. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y, Barlow C, Baltimore D, Wynshaw-Boris A, Kastan MB, Wang JY: Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 387:516, 1997
40. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB: Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57:837, 1997
41. Graff JR, Herman JG, Myohanen S, Baylin S, Vertino PM: Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem 272:22322, 1997
42. Chissoe SL, Bodenteich A, Wang Y, Jian L, Burian D, Crabtree JS, Freeman A, Hamed OS, McLaury H, Pan H, Toth S, Wang Z, Zhang G, Clifton S, Groffen J, Heisterkamp N, Roe BA: Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics 27:67, 1995